JAK

LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023

Retrieved on: 
Saturday, March 18, 2023
Managed Care, Pharmaceutical, Health, Clinical Trials, Janus, American Academy of Dermatology, American Academy, JAK, IGA, Leo Pharma, Patient, AAD, CHE, DELTA, Week, Safety, LEO, Pharmaceutical industry, Silviculture

The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.

Key Points: 
  • The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.
  • A significantly greater proportion of delgocitinib-treated patients, compared to cream vehicle, achieved this IGA-CHE improvement (19.7% vs. 9.9%; p=0.006).
  • A significantly greater proportion of delgocitinib-treated patients achieved a ≥75% improvement in Hand Eczema Severity Index (HECSI-75) compared to cream vehicle (49.2% vs. 23.5%; p
  • We are incredibly excited to share the positive results of this trial, which demonstrates the potential that delgocitinib cream has as a first-in-class innovative topical treatment.”

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023
Constellation, Progression-free survival, Cancer, Research, Conference, FSE, Workforce, Lenalidomide, DLBCL, Webcast, Significant event audit, Lymphoma, Saskatchewan River Sturgeon Management Board, Tafasitamab, Patient, ASH, JAK, Safety, Conference call, Doctor of Philosophy, Cryptocurrency, Video game, Pharmaceutical industry, Ruxolitinib, Novartis, MorphoSys

MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.

Key Points: 
  • MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the fourth quarter  2022 and € 3.0 million for the full year of 2022.
  • Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
  • This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 15, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Constellation, Progression-free survival, Cancer, FSE, Workforce, Lenalidomide, DLBCL, Significant event audit, Lymphoma, Saskatchewan River Sturgeon Management Board, Tafasitamab, Patient, ASH, JAK, Safety, Doctor of Philosophy, Video game, Pharmaceutical industry, Ruxolitinib, Novartis, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.
  • MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
  • Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
  • This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

OnQuality Pharmaceuticals Announces Presentations of OQL025 and OQL06x, at the AACR Annual Meeting

Retrieved on: 
Wednesday, March 15, 2023
AACR, Face, Quality of life, Human, Diarrhea, Skin, Neck, Patient, Toxicity, EGFR, JAK, Cancer, Incidence, Rash, Dehydration, American Association for Cancer Research, Gastrointestinal tract, Pulmonary toxicity, Lung, Pharmaceutical industry

EGFR inhibitors are a class of drugs commonly used in the treatment of various cancers, including lung and colorectal.

Key Points: 
  • EGFR inhibitors are a class of drugs commonly used in the treatment of various cancers, including lung and colorectal.
  • The most common skin toxicity associated with EGFR inhibitors is acneiform rash, which frequently appears on the face, neck, upper chest, and back.
  • To address this significant unmet need, OnQuality is developing OQL025 and OQL06x.
  • "OQL025 and OQL06x are first-in-disease drug candidates for EGFR inhibitor-induced skin rash and diarrhea."

ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata

Retrieved on: 
Wednesday, March 8, 2023
Janus, MD, SAN, Atopic dermatitis, AA, Hair loss, Skin, KOL, IP, Granuloma annulare, ASLN, Yale University, Scalp, JAK, Vitiligo, Yale School of Medicine, Patient, Associate, Autoimmune disease, Hair, DHODH, Immune privilege, Lichen planus, Alopecia areata, Sarcoidosis, Pharmaceutical industry, Dermatology

Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.

Key Points: 
  • Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.
  • ASLAN plans to initiate a proof-of-concept study of farudodstat in AA in the second quarter of 2023.
  • A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN’s website .
  • He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, erosive lichen planus, and other disorders.

Ajax Therapeutics Appoints Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Computational chemistry, JAK2, DMPK, Chemistry, BET, IND, Novartis Institute for Tropical Diseases, Novartis, Nimbus, University, Pancreatic serous cystadenoma, Biocon, IDH1, Forma, Therapy, Biomedical Research, Patient, JAK, Disease, Drug development, Preclinical development, Ajax, Doctor of Philosophy, TYK2, Sanofi, MPN, Senior, Pharmaceutical industry, Safety

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development.

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development.
  • Dr. Collis brings over 25 years of drug development experience to Ajax with previous preclinical development roles at Novartis, Forma Therapeutics and Nimbus Therapeutics.
  • “We are excited to have Alan join Ajax as we transition our lead Type II JAK2 inhibitor program into IND enabling studies,” said Martin Vogelbaum, CEO of Ajax Therapeutics.
  • Prior to Syngene, he served as Senior Vice President of Preclinical Development at Nimbus Therapeutics where led the preclinical and IND activities for the company’s TYK2 and HPK-1 inhibitor programs.

Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update

Retrieved on: 
Monday, February 27, 2023
Janus, Orthostatic hypotension, Chronic obstructive pulmonary disease, Blood pressure, JAK, Telephone, Atrophy, Norepinephrine, SG, American Autonomic Society, GSK, Internet, MBA, Research, Noh, Owens & Minor, Executive, Maintenance, J.P. Morgan & Co., Partnership, Webcast, FDA, Patient, R, MSA, Janssen, Growth, Research and development, Wesleyan University, COPD, Bank statement, CIBC, CIBC World Markets, Columbia University, Hypertension, Asthma, Sale, BA, Merrill (company), Multiple system atrophy, Medication, Administration, Pharmaceutical industry, Cryptocurrency, Beauty salon, Holding company, Fine chemical, Management, Viatris

Revenue: Total revenue for the fourth quarter of 2022 was $14.6 million, almost entirely comprised of $14.6 million in Viatris collaboration revenue.

Key Points: 
  • Revenue: Total revenue for the fourth quarter of 2022 was $14.6 million, almost entirely comprised of $14.6 million in Viatris collaboration revenue.
  • In the fourth quarter of 2022, Theravance Biopharma recognized its first revenue associated with non-US YUPELRI royalties.
  • Cash burn in fourth quarter of 2022 was $7 million excluding a $118 million tax payment and $34 million of share repurchases.
  • A replay of the webcast will be available on Theravance Biopharma's website for 30 days through March 29, 2023.

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Retrieved on: 
Monday, February 27, 2023
JAK, Safety, Cate, Doctor of Philosophy, Hugo, FRCPC, Filgotinib, CET, JAK1, Research, Anemia, Patient, LTE, Abstract, Quality of life (healthcare), Ulcerative colitis, RA, Rheumatoid arthritis, ECCO, European, Congress, Western University, Epidemiology, IBD, Galapagos NV, Euronext, Pharmaceutical industry, Biostatistics, MD, UC, Galápagos Islands, Immunology

A number of abstracts will present analyses from the SELECTION program with filgotinib.

Key Points: 
  • A number of abstracts will present analyses from the SELECTION program with filgotinib.
  • Additionally, Galapagos will present pooled data from five Phase 2/3 trials, and two long-term extension trials of filgotinib designed to further understand the safety profile of filgotinib in UC and rheumatoid arthritis (RA).
  • “We are excited to present data from multiple studies of filgotinib in UC, including results from the SELECTIONLTE study, which has been selected amongst the top 11 oral abstracts at ECCO,” said Daniele D’Ambrosio, MD, PhD, Therapeutic Area Head, of Immunology, at Galapagos.
  • Amongst subjects who completed the study, the reduction in mean pMCS in SELECTION was maintained up to LTE Week 144.

Galapagos announces full year 2022 results and outlook for 2023

Retrieved on: 
Thursday, February 23, 2023
Real-World Evidence, JAK, Baltic, Civil service commission, CD19, Filgotinib, CET, UC, DM, Drug discovery, Collaboration, Patient, SLE, Exercise, Bank statement, Acceleration, BCMA, European Commission, TYK2, Depreciation, D, Multiple myeloma, Axial spondyloarthritis, Annual report, PRAC, Cryptocurrency, Pharmaceutical industry, Central Europe, EU

We reported product net sales of Jyseleca® in Europe in 2022 amounting to €87.6 million, compared to €14.8 million last year.

Key Points: 
  • We reported product net sales of Jyseleca® in Europe in 2022 amounting to €87.6 million, compared to €14.8 million last year.
  • Cost of sales related to Jyseleca® net sales in 2022 amounted to €12.1 million, compared to €1.6 million in 2021.
  • We also recognized royalty income from Gilead for Jyseleca® for €10.7 million in 2022 (compared to €3.8 million in 2021).
  • We aim to publish the fully audited annual report for the full year 2022 on, or around, 23 March 2023.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, February 23, 2023
Janus, JAK, Safety, Therapy, Half-life, Psoriatic arthritis, PD, Atopic dermatitis, MK2, Research, IND, Acquisition, Eli Lilly, Patient, R, MAD, RA, Methotrexate, Hidradenitis suppurativa, Plasma, HS, Rheumatoid arthritis, Pediatrix Medical Group, Ulcerative colitis, AD, ACRS, Confluence, PK, G&A, Pharmacokinetics, Pharmaceutical industry, Vaccine, Cryptocurrency, Video game, Hydraulic machinery

Aclaris initiated a Phase 1 MAD (multiple ascending dose) trial of ATI-2138 in healthy volunteers in December of 2022.

Key Points: 
  • Aclaris initiated a Phase 1 MAD (multiple ascending dose) trial of ATI-2138 in healthy volunteers in December of 2022.
  • Aggregate cash, cash equivalents and marketable securities as of December 31, 2022 included proceeds received during the fourth quarter under a license agreement with Pediatrix Therapeutics, Inc. (Pediatrix).
  • Net loss was $27.6 million for the fourth quarter of 2022 compared to $22.8 million for the fourth quarter of 2021.
  • Total revenue was $7.8 million for the fourth quarter of 2022 compared to $1.5 million for the fourth quarter of 2021.